Oklo Shares Sink as Analyst Downgrades and Surging 2026 Spending Spark Valuation Reset
Shares of Oklo Inc. (OKLO) are underperforming the broader market Monday, sliding more than 4% as investors react to a series of aggressive price target cuts from Wall Street. The downward move follows a recent earnings report that revealed a wider-than-expected loss and a massive projected increase in capital expenditures for the 2026 fiscal year.
Wall Street Slashes Targets Amid Execution Concerns
Oklo Inc. (OKLO) is experiencing a sharp intraday decline of 4.12%, with shares trading at $48.16. This move represents a significant decoupling from the S&P 500, which is up 0.14% in the same period. The primary catalyst for today's weakness is a "valuation reset" led by major investment banks. UBS recently slashed its price target on OKLO from $95 to $60, maintaining a Neutral rating but citing heightened execution risks and the potential for cost overruns as the company moves toward commercializing its Aurora microreactor.
UBS was not alone in its caution. Goldman Sachs also reduced its price target to $65 from $91, while Citigroup lowered its outlook to $73.50. Analysts are increasingly focused on the transition from a speculative growth story to a capital-intensive industrial reality. The consensus among these firms is that while the long-term potential for nuclear energy to power AI data centers remains intact, the near-term path is fraught with regulatory and financial hurdles.
Surging 2026 Spending Guidance Weighs on Sentiment
The negative sentiment was exacerbated by the company's recent Q4 2025 financial results and subsequent 2026 guidance. Oklo reported a net loss of $0.27 per share, missing the analyst consensus of a $0.17 loss. More concerning for the market was the company's outlook for 2026 cash usage. Management guided for operating cash burn between $80 million and $100 million, with an additional $350 million to $450 million earmarked for investing activities.
As a pre-revenue company, this level of spending raises the specter of further equity dilution, despite Oklo ending 2025 with $1.4 billion in cash and raising another $1.18 billion in early 2026. Investors are clearly reassessing the risk-reward profile of the stock as the timeline for meaningful revenue remains years away, with the first reactors at Idaho National Laboratory not expected to be operational until late 2027 or 2028.
Insider Selling and Strategic Partnerships
Adding to the downward pressure is a trend of persistent insider selling. SEC filings from earlier this month revealed that CEO Jacob DeWitte and CFO Craig Bealmear sold significant portions of their holdings, totaling millions of dollars. While such sales are often scheduled, the timing—occurring alongside a 30% year-to-date decline in the stock—has dampened retail investor confidence.
In an attempt to offset the negative narrative, Oklo announced an expansion of its strategic partnership with Swedish firm Blykalla AB this morning. The collaboration aims to accelerate the commercialization of fast reactors through joint technical workstreams. However, the market has largely ignored this development, focusing instead on the immediate financial pressures and the broader rotation out of speculative "green energy" names. As oil prices remain volatile due to geopolitical tensions in the Middle East, capital is shifting toward established energy producers and defensive utilities like Dominion Energy, leaving high-beta names like Oklo vulnerable to further technical breakdowns.
Key Takeaways
- UBS and Goldman Sachs led a wave of price target cuts, with UBS slashing its target by 37% to $60.
- Management guided for a massive increase in 2026 spending, with up to $450 million projected for investing activities.
- The stock is down over 4% today, continuing a broader 'valuation reset' following a disappointing Q4 earnings miss.
- Persistent insider selling by the CEO and CFO has further weighed on investor sentiment during the March pullback.